FDA
-
-
-
-
-
-
-
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
-
-
-
-
-
-
-
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
-
-
-
-
-
-
-
Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies
-
-
-
-
-
-
-
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
OS Therapies (OSTX) Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
-
-
-
-
-
-
-
OS Therapies Provides Corporate Update
-
-
-
-
-
-
-
OS Therapies (OSTX) Prices 1.5M Unit Offering at $4/unit
-
323,590 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

